UNION KOREA PHARM Issues 51.66 Million New Shares via Debt-to-Equity Swap Under Rehabilitation Plan, Massive Dilution Ahead
Capital increase decision: Issuance of 51,660,308 new shares at 500 KRW per share, representing approximately 653% dilution relative to current outstanding shares, for debt-to-equity conversion under court-approved rehabilitation.
Use of proceeds: The funds will be used to repay rehabilitation secured claims and rehabilitation claims through equity conversion, with no new cash inflow.
Change of controlling shareholder: The largest shareholder is expected to change following the conversion, and fractional shares will be cancelled without compensation.
Trading halt since October 2024: No market price formation; reference price is based on valuation.
[AI Summary]The mandatory debt-to-equity swap under rehabilitation scheme inevitably dilutes existing shareholders. Short-term selling pressure likely, but long-term financial restructuring may stabilize the company. Investors should monitor dilution scale and rehabilitation progress.
KOSDAQ Filing Information
[Correction of Description] Report on Major Events (Decision on Paid-in Capital Increase)